AUTH/3197/4/19: Anonymous v Ethypharm — sponsored opioid therapy review service (no breach) | PMCPA Case

📊

Key facts

⌄

Case	AUTH/3197/4/19
Parties	Anonymous v Ethypharm Limited
Topic	Sponsored therapy review service (opioid usage review)
Applicable Code year	2016
Complaint received	30 April 2019
Case completed	14 October 2020
Allegation focus	Third-party internal email implying linkage between therapy reviews and “client product/therapy priorities”; alleged commercial bias/disguised promotion; alleged Clause 2 breach
Company position	Engagement at design phase only; no approved materials/instructions/training plans; launch delayed pending review; intended non-promotional service with GP-led decisions
Decision	No breach (Clauses 19.2, 12.1, 9.1, 2)
Appeal	Appeal by complainants (re Clause 9.1) unsuccessful; Panel ruling upheld
Sanctions	None

Download the full case report (PDF)

Reviewed by Dr Anzal Qurbain (FFPM) — ABPI Final Signatory

🤖

Got a question about this case?

Ask one of our 13 specialist ABPI advisors — instant answers, 24/7.

Ask AskAnzal AI

🎬 Expert Video Walkthrough

🎬

Video walkthrough — coming for members

Subscribe now and get expert video analysis for every case as we publish them.

Subscribe — from £299/yr

📋

What happened

⌄

An anonymous contactable group (describing itself as GPs, NHS leaders, pharmacists, NHS patients and staff from a named third-party service provider) complained about therapy review services delivered by that third party for multiple pharma companies, including Ethypharm.
The Ethypharm-related service referenced in the third party’s internal email concerned an opioid usage review described as being “launched” in a named region with a view to expansion.
The complaint centred on an internal email (14 August 2018) from a senior third-party employee to its clinical team, which included the phrase about needing to “transition and integrate client product/therapy priorities into our internal resource and schedules”.
Complainants alleged this showed commercial bias (therapy reviews linked to sponsor products/ROI), lack of transparency, and that it amounted to disguised promotion; they alleged a breach of Clause 2.
Ethypharm said its engagement with the third party was only at design/development stage; no materials, instructions, briefings or training plans had been approved via medical sign-off and therefore were not available for circulation. Ethypharm delayed any launch pending the Panel’s consideration.
The Panel reviewed the email in full (context across multiple company clients) and noted it gave an extremely concerning impression overall, including that some reviews elsewhere in the email were linked to specific products and that the email might be seen as instructions to pharmacists.
However, for Ethypharm specifically, the email did not name an Ethypharm medicine or link the proposed opioid review to a specific Ethypharm product, and there was no evidence about the actual arrangements for the Ethypharm review beyond early development.

⚖️

Outcome

⌄

No breach of the Code was ruled in relation to Ethypharm.
The Panel ruled no breach of Clauses 19.2 and 12.1 (2016 Code) and therefore no breach of Clauses 9.1 and 2.
The complainants appealed the ruling of no breach of Clause 9.1; the Appeal Board upheld the Panel’s decision and the appeal was unsuccessful.

🔒

Unlock the full case analysis

Members get the complete breakdown — Clauses, Sanction, Signatory Lens, Audit checklist, and 3 Key Questions.

Best value

£249/year

Annual — save £99

£29/mo

Monthly

Join Now — Instant Access

AUTH/3197/4/19: Anonymous v Ethypharm — sponsored opioid therapy review service (no breach)

Key facts

What happened

Outcome

Clauses

Unlock the full case analysis

AQP Flagship Path — the complete UK ABPI signatory programme

📰 Weekly PMCPA Case Breakdown